Page 1582 - Small Animal Internal Medicine, 6th Edition

1554 Index

Corticosteroid(s) (Continued) Cryptosporidia, 488–489 Cytology (Continued) Diabetes insipidus, 741–746
immune-mediated disorders treated Cryptosporidiosis, 965–966 hematopoietic tissue, 1259 arginine vasopressin in, 741–742, 745f
with, 1222, 1222b Cryptosporidium spp., 488, 1533t–1535t, hyperplastic processes, 1259 central, 654t–655t, 741t, 742, 742b
VetBooks.ir neutrophilia induced by, 1376 C. canis, 965–966 impression smears, 1258 clinical signs of, 742–743
immune-mediated polyarthritis
clinical features of, 742–743
immune-mediated thrombocytopenia
1537
findings, 1246, 1246f
treated with, 1243
desmopressin acetate and, 744
C. felis, 965–966
pulmonary parenchymal disorders
C. parvum, 1428f, 1432, 1537, 1537f
etiology of, 741–742
treated with, 381 Crystalloid solutions, 916 infectious diseases, 1429–1430 diagnosis of, 743–745
inflammatory processes, 1259, 1259f
Corticosteroid-responsive neutropenia, Crystalluria, 669t lymph nodes, 1263–1264, 1264f modified water deprivation test for,
1375, 1375f Ctenocephalides felis, 1481, 1540, 1540f lymphoma, 1262f, 1299, 1300f 744, 744t
Cortisol, 867–868 Culture malignant cells, 1259–1263, 1260b nephrogenic, 654t–655t, 742, 742b
Cortisol-secreting adrenal tumors, fecal, bacterial, 414 mesenchymal tissue, 1259 physical examination of, 743
875–876 infectious disease evaluations, neoplasia, 1260f prognosis for, 746
Cortisone, 1222t 1431–1432 rickettsial diseases, 1430 random plasma osmolality
Costochondral junction, 6 nasal, 255–256 round cell tumors, 1261–1263, 1262f measurements for, 744–745
Cough Cutaneous lymphoma, 1295–1296, 1296f, sarcomas, 1260–1261, 1261f signalment, 742
cardiogenic pulmonary edema from, 3 1309 specimens treatment of, 745–746, 745b
causes of, 289b Cutaneous mast cell tumors, 1333 interpretation of, 1258–1264 urine specific gravity in, 743f
in dogs, 283b Cutaneous T-cell lymphoma, 1295–1296 staining of, 1258 Diabetes mellitus, 654t–655t
in laryngeal diseases, 271 Cutaneous toxoplasmosis, 1522 Cytoprotective agents, 439–440, 439t in cats, 830–840
in lower respiratory tract disorders, Cutaneous trunci reflex, 1049t, Cytosine arabinoside (Cytosar), 1121b, classification of, 830–832
282–283 1050–1051, 1051f 1185t–1186t, 1320 clinical features of, 832–833
nonproductive, 282 Cutaneous xanthomas, 910 Cytotec. see Misoprostol diagnosis of, 833–834
productive, 282, 283b Cyanosis Cytoxan. see Cyclophosphamide etiology of, 830–832
Cough suppressants cardiac anomalies that cause, 113–116 D history in, 832
canine infectious tracheobronchitis definition of, 284 monitoring techniques for, 835–836
treated with, 323, 323t hypoxemia and, 284 Dacryocytosis, 1386 non-insulin-dependent diabetes
in tracheal collapse, 336 Cyanotic mucous membranes, 5b Dalteparin sodium mellitus, 830, 831f
Cough syncope, 3 Cyclooxygenase-2 (COX-2) inhibitors, arterial thromboembolism in cats obesity, 834
“Cough-drop,”, 3 for acute pancreatitis, 628–631 treated with, 227b physical examination of, 833
Coumadin. see Warfarin Cyclophosphamide, 386t–388t, 1204t, dosage of, 229 plantigrade posture associated with,
Coxiella burnetii, 1481, 1533t–1535t, 1209t–1210t Dazzle reflex, 1085–1086 832, 833f
1542–1543 Cyclosporin A, 1227t DDAVP. see Desmopressin prognosis for, 840
Coxofemoral joint, arthrocentesis Cyclosporine, 442, 515t–517t, 592–593, D-dimers, 355 remission of, 830–832, 832b,
method in, 1191f 1224–1226 Decerebrate rigidity, 1044, 1044f 836–837
Crackles, 285–286 granulomatous meningoencephalitis Decompensated congestive heart failure, risk factors of, 832
Cranial abdominal pain, 625f–626f treated with, 1121b 62b, 129 sequence of events in, 832f
Cranial nerves. see also specific nerve immune-mediated diseases treated Decompressive cystocentesis, 726f signalment, 832
examination of, 1054–1060 with, 1255t–1256t Decrescendo murmurs, 9–10 treatment of, 834–840
function of, 1057t description of, 1225t–1226t Deep pain, 1052f diet, 834–835
optic nerve, 1055, 1056t hemolytic anemia, 1236 Degenerative joint disease, 1195–1196, glipizide, 835
regional assessment of, 1056t polyarthritis, 1204t 1196f, 1197t insulin, 834–836
Cranial-caudal diameter, 21–22 joint disease treated with, 1209t–1210t Degenerative myelopathy, 1148–1149 oral hypoglycemic drugs,
C-reactive protein, 1217–1218, 1425 myasthenia gravis treated with, 1251t Degenerative valvular disease, heart 835–837
Creatinine neurologic disorders treated with, sounds and, 9 sulfonylureas, 835
glomerular function, diagnostic tests 1185t–1186t Delayed puberty, 953 in dogs, 809–830
for, 658 Cylindrical bronchiectasis, 290 DeLee mucous trap, 1009f breeds commonly affected, 809,
in Greyhounds, 1362 Cyproheptadine, 386t–388t, 515t–517t Demerol. see Meperidine 810t
serum, 658–659 Cyst(s) Depo-Medrol. see Methylprednisolone cataracts secondary to, 809–810,
Creatinine clearance, 660–661, 661t biliary, 575 acetate 810f, 828–829
Crenosoma vulpis follicular, 954, 954f Deracoxib (Deramaxx), 1209t–1210t, classification of, 809
lower respiratory tract diseases caused luteal ovarian, 955f 1268t, 1327b clinical features of, 809–810
by, 296, 297f, 297t ovarian, 955–956, 955f–956f Dermacentor variabilis, 1169, 1473, 1479 clinicopathologic abnormalities in,
pulmonary parenchymal diseases pericardial, 175–176 Dermatologic disorders, 1031–1032, 811b
caused by, 346 rete ovarii, 956 1032f complications of, 812b, 828–830
Cretinism, 772–773, 772b, 773f spinal articular, 1147 Dermatomyositis, 1177, 1177f, 1253 concurrent diseases, 810, 817
Cricopharyngeal achalasia/dysfunction, Cystatin C, 659 Dermatophytes, 1533t–1535t diabetic nephropathy caused by, 829
451–452 Cystic benign prostatic hyperplasia, Dermoepidermal mass, 1263f diabetic neuropathy caused by, 829
Cricothyroid ligament, 300, 301f 1001–1003, 1002f Dermoepidermal mast cell tumors, diagnosis of, 811
Crossed extensor reflex, 1049–1050 Cystic endometrial hyperplasia, 985–988, 1329f, 1333 etiology of, 809
Cross-matching, 1357 986f–987f, 987t Deslorelin, 1034t–1036t history in, 809–810, 818
Crotalus atrox toxoid vaccine, 1455 Cystic meningioma, 1067f Desmopressin, 663 insulin-dependent diabetes mellitus,
Cryopoor plasma, 1355–1356 Cystine urolithiasis, 721–722 diabetes insipidus, 744 809
Cryoprecipitate, 1356 Cystitis indications for, 896t–897t lens-induced uveitis caused by, 829
Cryptococcal antigen latex agglutination feline idiopathic. see Feline idiopathic von Willebrand disease, 1399 monitoring techniques for, 818–830
serology, 1128 cystitis Desoxycorticosterone pivalate, 876, blood glucose concentrations, 818
Cryptococcosis, 1507–1510 hemorrhagic, 1284 896t–897t continuous glucose-monitoring
ancillary tests for, 1118t Cystocentesis, 650–651, 664 Desquamative dermatopathy, 1296f systems, 821
central nervous system signs of, 1508 Cystoliths, 713f Dexamethasone, 386t–388t, 441, objective of, 818
chorioretinitis caused by, 242f Cystometrography, 672, 732b 515t–517t, 1034t–1036t serial blood glucose curves,
clinical features of, 1507–1508, 1508f Cystourethrography, 707–708 immune-mediated diseases treated 819–822, 820f, 823f–824f
cytologic diagnosis of, 1509, 1509f Cystourethroscopes, 947 with, 1222–1223, 1255t–1256t serum fructosamine
description of, 260 Cytauxzoon felis, 1430, 1516, 1516f pregnancy termination using, 960 concentrations, 818–819
diagnosis of, 1508–1509, 1509f Cytauxzoonosis, 1516–1517 properties of, 1222t urine glucose, 819
epidemiology of, 1507 Cytochrome P450 enzymes, 89 Dexamethasone sodium phosphate, physical examination of, 810, 818
etiology of, 1507 Cytology, 1257–1264 896t–897t prognosis for, 830
facial deformity caused by, 242f, bacterial diseases, 1429–1430 Dexamethasone suppression test signalment for, 809, 810t
245–246 blastomycosis findings, 1503f, 1503t in cats, 881–882, 881t, 882f systemic hypertension and, 830
prevention of, 1510 canine monocytotropic ehrlichiosis, high-dose, 864–865, 866t, 871 treatment of, 811–818
radiographic signs of, 249b 1475–1476, 1475f low-dose, 864–865, 866t, 867–868, diet, 816, 816b
treatment of, 1509–1510 carcinomas, 1260, 1261f 869f exercise, 816–817
zoonotic aspects of, 1510 cryptococcosis, 1509, 1509f oral, 866t, 870 goal for, 811, 812t
Cryptococcus spp., 1503t epithelial tissue, 1258–1259 Dexrazoxane, 1284 insulin, 812–814, 813t, 814–816,
C. gattii, 1128, 1507 fine-needle aspiration, 1257–1258 Dextrocardia, 326 815f, 815t
C. neoformans, 260, 1128, 1507, 1509f fungal diseases, 1430 Dextromethorphan, 323, 323t, 386t–388t weight loss, 816
Cryptorchidism, 990–991, 991f general considerations for, 1257 Dextrose, 1185t–1186t endocrine alopecia caused by, 748t